ArticleBMC cancer2022

Safety and efficacy of irinotecan, oxaliplatin, and capecitabine (XELOXIRI) regimen with or without targeted drugs in patients with metastatic colorectal cancer: a retrospective cohort study.

Xiu Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.